Evidence map›Paper›PMID 38873848›Full record

ArticleMedical physics2024

Simultaneous dose and dose rate optimization via dose modifying factor modeling for FLASH effective dose.

Jiangjun Ma, Yuting Lin, Min Tang, Ya-Nan Zhu, Gregory N Gan, Ronny L Rotondo, Ronald C Chen, Hao Gao

Abstract read
In one paragraph

Article in Medical physics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiangjun MaInstitute of Natural Sciences and School of Mathematics, Shanghai Jiao Tong University, Shanghai, China.
Yuting LinDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas city, Kansas, USA.
Min TangInstitute of Natural Sciences and School of Mathematics, Shanghai Jiao Tong University, Shanghai, China.
Ya-Nan ZhuDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas city, Kansas, USA.
Gregory N GanDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas city, Kansas, USA.
Ronny L RotondoDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas city, Kansas, USA.
Ronald C ChenDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas city, Kansas, USA.
Hao GaoDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas city, Kansas, USA.

Funding

Novel Optimization Methods and Treatment Planning System for Clinically-Deliverable Truly-Hybrid Proton-Photon RadiotherapyR37CA250921 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Hao Gao · 2021 to 2026
$2.2M
Simultaneous dose and dose rate optimization for clinical FLASH proton radiotherapyR01CA261964 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GAO, HAO · 2022 to 2025
$2.0M
NCI NIH HHS R01 CA261964NCI NIH HHS R37 CA250921NIH HHS R01CA261964NIH HHS R37CA250921
6 · The paper itself

Abstract

backgroundAlthough the FLASH radiotherapy (FLASH) can improve the sparing of organs-at-risk (OAR) via the FLASH effect, it is generally a tradeoff between the physical dose coverage and the biological FLASH coverage, for which the concept of FLASH effective dose (FED) is needed to quantify the net improvement of FLASH, compared to the conventional radiotherapy (CONV). PURPOSE: This work will develop the first-of-its-kind treatment planning method called simultaneous dose and dose rate optimization via dose modifying factor modeling (SDDRO-DMF) for proton FLASH that directly optimizes FED.

methodsSDDRO-DMF models and optimizes FED using FLASH dose modifying factor (DMF) models, which can be classified into two categories: (1) the phenomenological model of the FLASH effect, such as the FLASH effectiveness model (FEM); (2) the mechanistic model of the FLASH radiobiology, such as the radiolytic oxygen depletion (ROD) model. The general framework of SDDRO-DMF will be developed, with specific DMF models using FEM and ROD, as a demonstration of general applicability of SDDRO-DMF for proton FLASH via transmission beams (TB) or Bragg peaks (BP) with single-field or multi-field irradiation. The FLASH dose rate is modeled as pencil beam scanning dose rate. The solution algorithm for solving the inverse optimization problem of SDDRO-DMF is based on iterative convex relaxation method.

resultsSDDRO-DMF is validated in comparison with IMPT and a state-of-the-art method called SDDRO, with demonstrated efficacy and improvement for reducing the high dose and the high-dose volume for OAR in terms of FED. For example, in a SBRT lung case of the dose-limiting factor that the max dose of brachial plexus should be no more than 26 Gy, only SDDRO-DMF met this max dose constraint; moreover, SDDRO-DMF completely eliminated the high-dose (V70%) volume to zero for CTV10mm (a high-dose region as a 10 mm ring expansion of CTV).

conclusionWe have proposed a new proton FLASH optimization method called SDDRO-DMF that directly optimizes FED using phenomenological or mechanistic models of DMF, and have demonstrated the efficacy of SDDO-DMF in reducing the high-dose volume or/and the high-dose value for OAR, compared to IMPT and a state-of-the-art method SDDRO.

Indexed as

Radiotherapy DosageRadiotherapy Planning, Computer-AssistedHumansModels, BiologicalOrgans at RiskProton TherapyRadiation Dosagedose rate optimizationFLASHinverse optimizationproton therapySDDROtreatment planning

Identifiers

PMID38873848
PMCPMC11783338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.